Li Lianghua, Wan Liangrong, Zhao Haitao, Wang Cheng, Wei Weijun, Liu Jianjun
Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Quant Imaging Med Surg. 2023 Aug 1;13(8):5182-5194. doi: 10.21037/qims-22-1418. Epub 2023 Jun 21.
[F]F-FDG, [Ga]Ga-PSMA-11, and [Ga]Ga-FAPI-04 have achieved good results in multiple clinical trials and clinical practice, but the imaging of these tracers is limited to traditional short-axis positron emission tomography/computed tomography (PET/CT). Therefore, we aimed to use total-body PET/CT dynamic scanning to describe whole-body biodistribution of these three tracers and to calculate more precise radiation doses.
Total-body PET/CT (uExplorer, United Imaging Healthcare) dynamic scanning was performed on 54 patients, including 30 patients with [F]F-FDG, 10 patients with [Ga]Ga-PSMA-11, and 14 patients with [Ga]Ga-FAPI-04. A 60-minute dynamic scanning of whole body was performed simultaneously after bedside bolus injection of the corresponding tracers. The dynamic sequence of 92 frames was quantitatively analyzed by the Pmod4.0 software. Whole body biodistribution was calculated as time-activity curves (TACs) describing dynamic uptake patterns in the subject's major organs, followed by calculation of tracer kinetics and cumulative organ activity. Finally, combined with the OLINDA/EXM software, effective doses of the different tracers and individual organ doses were calculated.
In a systematic TAC analysis of three tracers, we identified distinct biodistribution patterns in major organs. [Ga]Ga-PSMA-11 showed a trend of rapid increasing and slow decreasing in liver, spleen, muscle, and bone. In the heart, stomach, brain, and lung, tracer decreased rapidly after rapid increasing. Similarly, tracer uptake in the kidney and urinary bladder increased gradually. [Ga]Ga-FAPI-04 showed a rapid increasing and rapid decreasing trend in brain, lung, liver, spleen, bone, heart, kidney, and stomach. The mean effective dose of [Ga]Ga-PSMA-11 was 1.47E-02 mSv/MBq, and the mean effective doses of [F]F-FDG and [Ga]Ga-FAPI-04 were comparable (2.52E-02 mSv/MBq and 2.23E-02 mSv/MBq). The mean effective dose of [F]F-FDG was lower than that reported in the literature measured by previous short-axis PET, while both [Ga]Ga-PSMA-11 and [Ga]Ga-FAPI-04 had higher value than previously reported value.
[F]F-FDG, [Ga]Ga-PSMA-11 and [Ga]Ga-FAPI-04 have good biodistribution in human organs. Real-time high-sensitivity dynamic scanning with total-body PET/CT is a very effective way to accurately calculate biodistribution and effective dose of positron-labeled radiopharmaceuticals.
[F]F-FDG、[Ga]Ga-PSMA-11和[Ga]Ga-FAPI-04在多项临床试验和临床实践中取得了良好效果,但这些示踪剂的成像仅限于传统的短轴正电子发射断层扫描/计算机断层扫描(PET/CT)。因此,我们旨在通过全身PET/CT动态扫描来描述这三种示踪剂的全身生物分布,并计算更精确的辐射剂量。
对54例患者进行全身PET/CT(uExplorer,联影医疗)动态扫描,其中30例患者使用[F]F-FDG,10例患者使用[Ga]Ga-PSMA-11,14例患者使用[Ga]Ga-FAPI-04。在床边推注相应示踪剂后,同时进行60分钟的全身动态扫描。通过Pmod4.0软件对92帧的动态序列进行定量分析。将全身生物分布计算为时间-活度曲线(TAC),以描述受试者主要器官的动态摄取模式,随后计算示踪剂动力学和累积器官活度。最后,结合OLINDA/EXM软件,计算不同示踪剂的有效剂量和个体器官剂量。
在对三种示踪剂的系统TAC分析中,我们确定了主要器官中不同的生物分布模式。[Ga]Ga-PSMA-11在肝脏、脾脏、肌肉和骨骼中呈现快速上升和缓慢下降的趋势。在心脏、胃、脑和肺中,示踪剂在快速上升后迅速下降。同样,肾脏和膀胱中的示踪剂摄取逐渐增加。[Ga]Ga-FAPI-04在脑、肺、肝、脾、骨、心、肾和胃中呈现快速上升和快速下降的趋势。[Ga]Ga-PSMA-11的平均有效剂量为1.47E-02 mSv/MBq,[F]F-FDG和[Ga]Ga-FAPI-04的平均有效剂量相当(分别为2.52E-02 mSv/MBq和2.23E-02 mSv/MBq)。[F]F-FDG的平均有效剂量低于以往短轴PET测量的文献报道值,而[Ga]Ga-PSMA-11和[Ga]Ga-FAPI-04的值均高于先前报道值。
[F]F-FDG、[Ga]Ga-PSMA-11和[Ga]Ga-FAPI-04在人体器官中具有良好的生物分布。全身PET/CT实时高灵敏度动态扫描是准确计算正电子标记放射性药物生物分布和有效剂量的非常有效的方法。